Variation of the methoxycarbonyl and C-18 substituents of the antiaddictive compound 18-methoxycoronaridine, and contraction of its isoquinuclidine ring segment, provided 15 congeners for SAR evaluation at opioid and alpha3beta4 nicotinic acetylcholine receptors. The opioid activities were relatively low, and the alpha3beta4 nicotinic acetylcholine receptor activities were found to correlate...
Chemical substance abuse has tormented mankind throughout history. A number of chemical approaches have been employed in an attempt to treat chemical addiction. Unfortunately, most of these have proven unsuccessful though several chemical entities have been shown to be moderately effective. The naturally occurring alkaloid ibogaine has been reported to interrupt the cravings for alcohol,...
In a previous study it was observed that fluoxetine potentiates the stimulus effects of lysergic acid diethylamide (LSD). In the present investigation, stimulus control was established in groups of rats using as training drugs the hallucinogens lysergic acid diethylamide (LSD); 0.1 mg/kg), (-)-2,5-dimethoxy-4-methylamphetamine [(-)-DOM; 0.56 mg/kg], ibogaine (10 mg/kg), and...
Human FigurationsOctober 30, 2026Michael Dunning, Jason Hughes, Hannah Farrimond et al.
In April 2026, US President Donald Trump signed an executive order fast-tracking access to psilocybin and ibogaine for the treatment of serious mental illness. This follows decades in which psychedelics had been vilified as a group of drugs entirely lacking in therapeutic potential, associated with counter-cultural groups such as hippies, and whose use was both criminalised and widely...
Substance use disorders remain a leading cause of preventable death, and existing care is better described as disease management than as cure. Medications for opioid, alcohol, and tobacco use disorders reduce substance use, and opioid agonist treatment reduces mortality, yet retention is poor and functional recovery is rarely measured. This review asks whether psychedelics treat addiction, or...
A nationally representative cross‐sectional survey of U.S. adults found the among all psychedelics, ibogaine and 5‐MeO‐DMT (5‐methoxy‐N,N‐ dimethyltryptamine) resulted in the most frequent self‐reported adverse outcomes, according to a recent study. The study, “Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5‐MeO‐DMT,” by Otto Simonsson, Ph.D., and colleagues, was published...
Abstract: Background: The registry record of psychedelic and related rapid-acting compounds is large, heterogeneous and laborious to synthesize by hand. We tested whether a large language model (LLM) with live access to the ClinicalTrials.gov application programming interface (API) could produce a timely, structured and reproducible characterization of this landscape. Methods: Cross-sectional...
Surgical Neurology InternationalOctober 9, 2026Andrea Garcia-Bitar, Eduardo Jesus Castañeda, José Rafael Buenrostro-Rangel et al.
Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention,...
medRxivSeptember 10, 2026Mori Krantz, Mark C. Haigney, Mary Ross Southworth et al.
preprint
Background: Several Schedule I substances have demonstrated potential benefits for refractory psychiatric conditions and addiction. Some have been legalized at the state level, while others like kratom (mitragynine) are available over-the-counter in some states and illegal in others. A recent presidential executive order directs certain federal agencies to accelerate development and facilitate...
IntroductionOpioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.MethodsWe conducted a...